Business
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update
In April, SCYNEXIS announced positive top-line results from the Phase 3 VANISH-306 study evaluating oral ibrexafungerp for the treatment of Vulvovaginal
About this update from Scynexis, Inc.
[{"type":"text","content":"In April, SCYNEXIS announced positive top-line results from the Phase 3 VANISH-306 study evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as vaginal yeast infection. NDA submission for this indication is on track for the second half of 2020 Enrollment is ongoing in the Phase 3 CANDLE study of oral ibrexafungerp for the prevention of recurrent vaginal yeast infections; top-line results and supplemental NDA submission anticipated in the second half of 2021 In January, SCYNEXIS announced positive results from the second interim analysis of the ongoing Phase 3 FURI study, providing further evidence of oral ibrexafungerp’s ability to treat severe, often refractory, fungal infections. Enrollment continues in hospital-focused studies, including FURI, CARES (for Candida auris) and SCYNERGIA (for invasive aspergillosis) In April, SCYNEXIS strengthened its cash position from the sale of $10 million of convertible notes and gained additional financial flexibility by entering into a $20 million common stock purchase agreement; current cash runway past mid-2021 JERSEY CITY, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug resistant infections, today reported financial results for the quarter ended on March 31, 2020 and provided an update on recent clinical and corporate developments.\n “The past several months have seen major accomplishments by SCYNEXIS, as we continued to generate positive clinical data from both our vaginal yeast infection and hospital-based programs, while also enhancing both our current cash position and our financial flexibility going forward,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. “With the successful completion of our Phase 3 VANISH program, we remain on track to submit an NDA for ibrexafungerp as a treatment for vaginal yeast infections in the second half of this year, as we continue SCYNEXIS’s transition to a fully-integrated research and commercial entity. If approved, ibrexafungerp could represent the first new class of antifungals in over 20 years – a particularly significant achievement at a time when the need for novel anti-infectives has become devastatingly clear.” Ibrexafungerp Update Com...